Assessment of Cervical Cancer Prevention Practice among Female Health Workers at a Level Three Hospital in Port Harcourt, Nigeria.

Bassey Goddy¹, Nyengidiki K Tamunomie,[†]ohnson C Samuel,¹

¹Department of Obstetrics and Gynaecology, University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria.

Corresponding Author:

Dr Nyengidiki K Tamunomie University of Port Harcourt Teaching Hospital Port Harcourt, Rivers State, Nigeria **Phone no** +2348037109496 **Email:** tammynyengs@yahoo.com

| | How to cite this article: | | | |
|--------|--|--|--|--|
| | Bassey G, Nyengidiki KT, Johnson CS. Assessment of Cervical Cancer Prevention Practice | | | |
| | among Female Health Workers at a Level Three Hospital in Port Harcourt, Nigeria. | | | |
| | NDJMS 2020; 2 (3):7-16 | | | |
| \sim | | | | |

Received 24th December 2019 | Accepted 26th February 2020 | Published 27th April, 2020

Abstract

Background: Cervical cancer though a preventable malignancy is still prevalent in sub-Saharan African and the Human Papillomavirus is recognized as the principal causative agent. Preventive measures have been known to be effective and are provided by healthcare workers.

Objective: To determine the uptake of Human Papillomavirus vaccination and Papanicolaou Smear among female health workers at the University of Port Harcourt Teaching Hospital.

Methods: This was a cross-sectional study to determine the uptake of the Human Papillomavirus vaccine and Papanicolaou smear among female healthcare providers. A self-administered questionnaire was used to obtain relevant information from consenting respondents from the major departments in the hospital. Data obtained were entered and analyzed using SPSS version 21 software package.

Results: The uptake of Human Papillomavirus vaccine was 2.2% with only 11.3% been screened for cervical cancer by Pap smear. Three hundred and fifty-four 95.2%) had good knowledge of Human Papillomavirus vaccine, and 83.1% were aware of the vaccine. The high cost (45.1%) and inability to access (42.1%) the vaccine were the main reasons for the poor uptake of the vaccine. Three hundred and forty-two (94.0%) were willing to take the vaccine if available and affordable.

Conclusion: This study demonstrated a considerable disparity between knowledge and uptake of the Human Papillomavirus vaccine. The low participation in self prevention of cervical cancer may send wrong signals to the general populace, hence reduce community participation. The government at all levels should formulate programmes to ensure availability and utilization of Human Papillomavirus vaccine

Keywords: HPV vaccine, Uptake, Pap Smear, Health care providers, Port Harcourt.

Introduction

Cervical cancer is the second commonest cancer in women worldwide and infection with Oncogenic strains of human papillomavirus (HPV) types 16 and 18 are the most commonly implicated in cervical cancer.^{1,2} More than 450,000 cases of this preventable cancer are diagnosed worldwide each year, resulting in nearly a quarter of a million deaths with Sub-Saharan Africa accounting for 80% of the cases³⁻⁵.

Exact incidence of HPV is unknown, however 75% of individuals (males and females) will experience an HPV infection at least once in their lifetime with the highest rate of infection occurring in individuals under the age of 25. Over 50% of sexually active women are exposed to at least one HPV type during their lifetime. In a meta-analysis conducted by researchers in Spain, a global HPV prevalence of 11.7% was reported.⁷HPV prevalence in North America and Europe was estimated at 11.5% and 14.2% respectively, while the prevalence in Africa is estimated at 21.1% with sub-Saharan Africa topping the list at 24%.^{7,8} The high prevalence of HPV in Sub-Saharan Africa had been attributed to impairment of cellular immunity as a result of chronic cervical inflammation, parasitic infection, micronutrient deficiency, and HIV.⁹In Nigeria, HPV prevalence is high across all female ages but it is highest among 15-23 years old.¹⁰ Studies carried out in 22 countries, coordinated by the international agency for research on cancer (IRCC) identified HPV DNA in almost all 99.7% cases of cervical cancer¹.

About 40 distinct HPV types are known to infect the genital tract with at least 14 Oncogenic (or high risk) types significantly associated with progression to invasive cervical cancer (ICC).¹¹ Data on HPV type distribution in invasive and pre-invasive

cervical cancer is essential to predict the future impact of HPV16 and 18 vaccines and HPV screening tests.¹² World health organization projects that without immediate action, the global number of deaths from cervical cancer will increase by nearly 80% over the next decade, mainly in the low and middleincome countries like Nigeria. ¹³ Human Papillomavirus vaccines are 90 % effective in preventing infection from HPV subtypes 16 and 18, but only in females with no prior HPV 16 and 18 infection and because peak incidence of HPV occurs soon after the sexual debut, vaccination should be initiated before sexual activity is started.¹⁴⁻¹⁷ Therefore, young adolescent girls (aged 9-13) are appropriate target groups for HPV 18. vaccination as recommended by WHO. However, this age group is not usually targeted for vaccination.18 A study in Zimbabwe, revealed underutilization of HPV vaccines among healthcare providers.¹⁹ This was said to be due to low knowledge of HPV and HPV vaccines, psychosocial, cultural and logistical barriers to successful implementation, including cost, vaccine schedule, and hospital infrastructure. Also, a study in Tanzania revealed that the majority of health workers were aware of cervical cancer, but few were not aware of its cause or HPV vaccination.²⁰ A study in Cameroon revealed the non-accessibility of the HPV vaccine to 59% of a study population, as compared to 14.1% of health workers having access to HPV vaccine in a study done in Enugu (Nigeria)^{21,22}.

Healthcare workers are agents that propagate information about various health interventions. Their involvement in any health activity not only increases awareness but will act as a catalyst for other patients to partake in such interventions since they offer first-hand information based on experience. It is on this premise that this study seeks to determine the uptake of human Papillomavirus vaccination against cervical cancer among health workers at a tertiary health facility in Port Harcourt, Nigeria.

Materials and Methods

This was a cross sectional quantitative study among female health workers of the University of Port Harcourt Teaching Hospital towards the uptake of Human papillomavirus vaccine and Pap smear. The University of Port Harcourt Teaching Hospital is a level three hospital situate at Alakahia, Choba, Rivers State. It serves as a referral facility covering the South -South geographical regions of Nigeria. The investigators and their trained assistants administered well-structured open-ended questionnaires to consenting female health workers who include medical doctors, nurses, medical laboratory scientists, and pharmacists. Participants were from the major Departments of Obstetrics and Gynaecology, Surgery, Internal medicine, Paediatrics, laboratories, and Pharmacy. questionnaires Four Hundred were distributed among consenting female health workers until the required number was reached over two- month period from June 1st to 1st august 2019. Any non-

consenting female health worker is excluded from the study. Data obtained were age, parity, marital status, occupation, awareness of risk factors for cervical cancer, awareness of risk factors for human papilloma virus, awareness of its vaccination, uptake of human papillomavirus vaccines and previous Pap smear uptake. Awareness in this study is defined as the ability to be informed or being conscious of the subject discussed while knowledge is exhibition of facts and information about HPV and cervical cancer. The sample size was calculated from the formula²³ n=ZP(1-P)/d ²using a prevalence of uptake of HPV of 13.5% as reported by Dahlstrom et al²², tolerance error of 5% and an attrition rate of 10%. The determined minimum sample size for the study was 198. Data obtained was entered and analyzed using SPSS version 21 software package (Chicago) and data expressed in simple percentages and frequency tables.

Results

Three hundred and seventy-two questionnaires 372 out of the 400 questionnaires distributed had complete information for analysis.

Table 1: Sociodemographic indices ofrespondents

| Variable | Variable | Frequency | Percentage |
|----------------|--------------|-----------|------------|
| Age (years) | 20-29 | 112 | 30.1 |
| | 30-39 | 148 | 39.8 |
| | 40-49 | 90 | 25.8 |
| | 50 and above | 18 | 4.8 |
| Parity | 0 | 50 | 13.4 |
| | 1 | 112 | 30.0 |
| | 2-4 | 196 | 52.7 |
| | 5 and above | 36 | 9.7 |
| Marital status | Single | 76 | 20.4 |
| | Married | 296 | 79.6 |

The mean age of the respondents in the study was 34.46 ± 8.59 , with 39.8% (148) aged between 30-39 years. The mean parity was 1.53 ± 0.852 , and 10.2% were grand multipara. Medical doctors constituted 178(47.8%), while 90 (24.2%) were nurses, fifty-four (14.5%) were pharmacists and 50 (13.4%) were medical lab scientists. Christians constituted 344 (92.5), 20 (5.4) were Muslims, while African traditional accounted for 8 (2.2%).



Fig 1: Assessment of HPV and HPV vaccination knowledge

Out of all the respondents, 354 (95.2%) were aware of HPV, whereas, 18 (4.8%) did not have any knowledge of the virus. Figure 1 shows the awareness of HPV. Also, 344 (92.5%) of the individuals are aware that HPV is the most frequent cause of cervical cancer, while 28(7.5%) of the respondents lack such knowledge. Considering awareness of HPV vaccination 312 (83.9%) were aware while 60 (16.1%) were not.

| Risk factor | Variables | Frequency | Percentage | |
|---------------------|--------------|-----------|------------|--|
| Coitarche | <14 | 64 | 17.2 | |
| | 15-19 | 206 | 55.4 | |
| | 20-24 | 90 | 24.2 | |
| | 25 and above | 8 | 2.1 | |
| Contraceptives | COCP | 32 | 8.6 | |
| - | Condoms | 70 | 18.8 | |
| | Others | 266 | 71.5 | |
| | None | 4 | 1.1 | |
| | | | | |
| No. Sexual partners | None | 4 | 1.1 | |
| - | One | 312 | 83.8 | |
| | Two or more | 56 | 15.1 | |
| Previous STI | Yes | 83 | 22.4 | |
| | No | 352 | 77.6 | |
| Tobacco use | Yes | 20 | 5.4 | |
| | No | 352 | 94.6 | |
| Multiple Sexu | ial Yes | 69 | 18.5 | |
| Partners | No | 260 | 69.9 | |
| | No idea | 43 | 11.5 | |

Table 2: Risk factors for HPV infection

Four (1.1%) of the respondents had not been sexually exposed while 270 (72.6%) of the respondents had coitarche at less than 20 years with a mean age at coitarche of 18.2+3.72. Seventy (18.8%) of the respondents used condoms consistently for contraception while combined oral contraceptives (COCP) as a risk factor for cervical cancer was used as a form of contraceptive in 32 (8.6%) of respondents.

| Reasons | Variables | Frequency | Percentage |
|---------------|----------------------------|-----------|------------|
| | | | |
| Reasons for | Too Expensive | 164 | 45.7 |
| Non uptake of | Don't know where to get it | 82 | 22.5 |
| HPV vaccine | Vaccine not available | 68 | 18.7 |
| | Not necessary | 32 | 8.8 |
| | No reason | 18 | 4.9 |

Table 3: Reasons for non- uptake of HPV vaccines

Eight (2.2%) of the respondents have been vaccinated, while 364(97.8%) were yet to receive the vaccine. Considering the reasons for poor utilization of the vaccine, 32 (8.8%) believed that it was not necessary, 68 (18.7%) said the vaccines were not always available, 164 (45.1%) felt the vaccines were too expensive, 82 (22.5%) of the respondents claimed not to be aware of where to obtain the vaccine while 18 (4.9%) had no specific reason for not taking the vaccine. A total of 342 (94.0%) were willing to take the vaccines if made readily available and affordable 14 (3.8%) were not interested in the vaccine while 8 (2.2%) were yet undecided as shown in table 3.

| | Variables | Frequency | Percentage |
|--------------------------|---------------|-----------|------------|
| Uptake of Pap Smear | Yes | 42 | 11.3 |
| | No | 330 | 88.7 |
| Results of Smears | Positive | 8 | 19.1 |
| | Negative | 34 | 80.9 |
| | | | |
| Decessor (en Neu | NI-1 | 10 | 10 0 |
| Reasons for Non - | • Not aware | 42 | 12.7 |
| Uptake | Not necessary | 94 | 28.5 |
| | Expensive | 194 | 58.8 |

Table 4: Pap Smear Uptake and Reasons for non-uptake

Forty-two (11.3%) of the respondents had been screened for cervical cancer using Papanicolaou smear, and 34 (81%) were negative, while 8 (19%) had a positive PAP smear result. Responding to why the majority have not been screened, 42 (12.9) were not aware, 94 (28.5%) said it was not necessary, while 194 (58.8%) said the screening was too expensive.

Discussion

The role of healthcare providers in the strategy to reducing the burden of cervical cancer had been stressed in several studies. ²⁴⁻²⁶ Their role is further strengthened when they are partakers of what they offer to the patients that seek their services. Medical doctors accounted for most of the participants in this study, as they constituted a higher proportion of the

health workers and were more willing to participate in the survey than other health workers.

This study demonstrated a high level of knowledge and awareness of HPV among the female health workers interviewed; this high level of awareness and knowledge of HPV shown in this study is somewhat not surprising as most of the respondents were doctors and nurses and were likely to be exposed to the knowledge of HPV and cervical cancer as also demonstrated by McCarey et al. ²⁷The findings in this study are at variance with the observations in Botswana and in Latvia among adolescence where reports of awareness of 9% and 21.5% respectively were noted^{28,29}; although the population studied were not health workers. However higher levels of knowledge and awareness was demonstrated in a general population in a Canadian study. ³⁰ The Canadian study showed that 93.0% of the study population were aware of HPV, 64.5% were aware of the vaccine, and 91.0% understood the connection between HPV and cervical cancer ³⁰. The above information the demographic highlighted and occupational variations in the knowledge and awareness of an aetiological factor to cervical cancer.

Regarding the risk factors that can predispose to the HPV infection, the mean age of coitarche in this study was 18.2±3.72, which compares favourably with 14.25±2.7 reported in Nnewi, Nigeria and 16.2 years reported in Tanzania.^{31,32} This study showed that 17.2% of the respondents had coitarche at less than 15 years and as high as 72.6% had coitarche at less than 20 years implying that the study population is at higher risk of acquiring HPV infection and possibly cervical cancer. Non-use of barrier methods of contraception have been

associated with increased risk of acquisition of HPV infection and this survey indicates that less than one-fifth of the population practiced the above consistently. This finding was different from that noted in Nnewi, Nigeria and in Tanzania where as high as 56.3% and 50% respectively of the population studied used the male condom ^{31,32.} This is as a method of contraception important as consistent use of condoms is known to confer some protection against the acquisition of the virus ³³ The use of condoms amongst the respondents that are not married should be encouraged but this may not be practicable amongst the married and those with low parity.

There is an urgent need to emphasize modification behavioral towards sex among the study population as almost all respondents were sexually exposed irrespective of marital status with 12.9% attesting to having multiple sexual partners, 18.9% had spouses with other sexual partners and 22.6% had been treated for STI in the past which are risk factors for HPV infection. These findings place the respondents at significant risk of acquiring the HPV infection. Discouraging early marriage, premarital sexual relationships, and extramarital affairs may reduce the prevalence of HPV infection amongst the study population. Cigarette use is known to increase the risk of progression of various stages of HPV infection to invasive cancer, and it was observed that only 5.4% of the respondents admitted to cigarette smoking. Cigarette smoking is not an acceptable social norm in our society, and thus women who take cigarettes may not be willing to volunteer such information, and this may account for the few numbers of respondents who admitted to smoking in this study. This study revealed a considerable disparity between knowledge of HPV and uptake of vaccination. It is also quite

disheartening to find that only 12.9% of the respondents had had Pap smear screening and as low as 2.2% had ever been vaccinated against HPV. It would had been expected that among health workers, of whom are predominantly doctors and nurses, uptake should had been higher. Health care providers who had been screened and vaccinated are in a better position to share their experiences and to encourage their patients to undergo screening and to receive HPV vaccines. The therefore, to improve HPV effort, in the general vaccination uptake population in Nigeria must start with the education of the health care providers who will, in turn, influence the patients positively.

The poor utilization of HPV vaccines was also corroborated in another study in Nigeria, where 14.1 % was reported while the study in Canada; a developed country reported a high uptake of 84.0%. 22,29 Potential reasons for the poor uptake of the HPV vaccine were high cost of the vaccine and difficulty in accessing the vaccine. Therefore, subsidizing the cost of the vaccine and ensuring the availability of the vaccine will significantly improve the uptake of HPV vaccine amongst the study population and thus curb the menace of cervical cancer. If given the opportunity to take the vaccine free of charge, the majority indicated interest in receiving the vaccine. This finding is similar to the Kenyan study where 95% were willing to take up the vaccine if given the opportunity 34 . These observations support the Australian Government's action which launched the national free HPV vaccination program for females between the ages of 12 to 26 years which has significantly improved HPV vaccination in that country ³⁵. Similarly, in Denmark, the health insurance plan which covers for HPV vaccines has resulted in

80%, 75% and 62% successful uptake of the first, second and third doses of the vaccines respectively by eligible girls as of 200⁹.

Conclusion

Even though HPV vaccines are very effective in preventing cervical cancer, this study demonstrated a very low uptake of HPV vaccines among female health care providers in Port Harcourt Nigeria. The high cost of the vaccine and challenge in accessing the vaccines, were cited as the main reasons for the poor utilization of the vaccine. The study highlights the need that health providers themselves should be a target population to improving uptake. There is an urgent need for the hospital management as well as the government to formulate policies that will encourage the uptake of HPV vaccine and screening methods for cervical cancer, especially amongst the workforce of the hospital. These if done, would have a multiplier effect on other health personnel and filtering towards the general population at large

Reference

- Walboomers JM1, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol.* 1999 ;189(1):12-9.
- (2) Di Gusseppe G, Abbate R, Liguiri G, Albano L, Angelillo IF. Human papilloma virus and vaccination knowledge, attitude and behavioral intension in adolescents and young women in Italy. *Br J Cancer* 2008; **99**(2):225-9.
- (3) Parkin DM, Bary FL, Devesa SS. Cancer burden in 2000: the global picture. *Eur J Cancer* 2001:37 (suppl 8) S4- 66.

- (4)Lowndes CM. Editorial review. Vaccines for cervical cancer. *Epidemiol. Infect* 2006; **134**:1-12
- (5)Bosch FX, Lorinez A, Munos N, Meijer CJ, Shah KV. The causal relation between human papilloma virus and cervical cancer. J Clin Pathol. 2002; **55**:244-65
- (6)Trim K, Nagji N, Elit L, Roy K. Parent knowledge, attitude and behavior towards human papilloma virus vaccination for their children: a systemic review from 2001 to 2011.*Obstet Gynecol Int.* 2012; **2012**: 921236. doi: 10.1155/2012/921236
- (7)Dahlstrom LA, Tran TN, L Lundholm C, Young C, Sundstrom K. Attitude to HPV vaccination among parents of children aged 12-15 years. A Populationbased survey in Sudan. *Int J Cancer* 2010;**126**(2):500-7
- (8)Anorlu RL. Cervical cancer: the sub -Saharan African perspective. *Reprod Health Matters* 2008;**16**(32):41-9.
- (9)Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, DeHovitz JA et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. *Sex Transm Dis.* 1996;**23**(4):333-41
- (10) World health organization information centre on HPV and cervical cancers in Nigeria. Summary r e p o r t 2 0 1 0 . www.HPVcentre.Net/report/ NGA
- (11) Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J et all. Prevalence of human papillomavirus in cervical cancer: A worldwide

perspective. International biological study on cervical cancer (IBSCC) study group. *J Nat L cancer Inst* 1995; **87**:796-802

- (12) Smith JS, Lindsay L, Hoots B, Franceschi S, Winer R, Clifford GM. Human papilloma virus type distribution on invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. *Intl J Cancer* 2007; **121**:621-32
- (13) UICC calls for coordinated action against infections that contribute to global cancer burden (press release). Lyon France: International Agency for research on cancer (IARC), World health organization, February 4, 2010
- (14) Clifford G, Francechis S, Diaz M, Munos M, Villa LL. Chapter 3: HPV type distribution in women with and without cervical neoplastic disease. *Vaccine* 2006; 24:26-34.
- (15) Smith SJ, Lyndsay L, Hoots B. Human papilloma virus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. *International Journal of disease* 2007; **121**:621-32
- (16) Ault KA, Future 11 study group. Effect human of prophylactic papilloma virus, virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 3 and grade 2, adenocarcinoma in situ. A combined analysis of four randomized clinical trials. The lancet 2007;369(9576): 1861-8.
- (17) Paavonen J, Naud P, Salmcron J. Efficacy of human papilloma

virus (HPV) -16 and 18 ASO 4 adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV (PATRICIA): final analysis of a double-blind, randomized study in young women. *The lancet* 2009;**374**(15)308-14

- (18) WHO. Human papilloma virus vaccine: WHO position paper weekly epidemiological record 2009;84(15):118-31.
- (19) Sera EC, Paula CB, Rachel M, Leach M, Paul T. Healthcare providers perspective on the acceptability and uptake of HPV vaccines in Zimbabwe. *Journal of Obstetrics and Gynaecology* 2016;(37):147-155.
- (20) Remes P, Selestine V, Changalucha J, Ross DA, Wight D, Silvia de S et al. A qualitative study of HPV vaccine acceptability among health workers, teachers, parents, female pupils and religious leaders in North-West Tanzania. Vaccine 2012:30(36):5363-7
- (21) Catherine MC, David P, Pierre MT, Michel B, Anderson SD. Awareness of HPV and cervical cancer prevention among Cameroonian healthcare workers. *BMC women`s health* 2011,**11**:45. doi 1186/1472-6874-11-45
- (22) Ugwu EO, Obi SN, Ezechukwu pc, Okafor II, Ugwu AO. Acceptability of human papillomavirus vaccines and cervical cancer screening among health care workers in Enugu, South- East, Nigeria. *Niger J Clin Pract*. 2013;**16**(2):249-52
- (23) Mahajan BK. In: Mahajan BK (ed). Methods in Biostatistics for

Medical students and Research workers. 6th edition, New Delhi, Jaypee Brothers Med Publishers Itd 1997;88-102.

- (24) James O'Donovan, Charles O'Donovan, Shobhana Nagraj.The role of community health workers in cervical cancer screening in low income and middle-income countries: a systematic scoping review of the literature. *BMJ Global Health* 2019; **4**(3): e001452.
- (25) Dim CC. Towards improving cervical cancer screening in Nigeria: A review of the basics of cervical neoplasm and cytology, *Niger J Clin Pract*, 2012; **15** (3): 247-252
- (26) Ezem, B. U. Awareness and Uptake of cervical cancer in Owerri, South-East Nigeria. *Ann Afri Med*.2007; 6 (3):84-8
- (27) McCarey C, Pirek D, Tebeu PM, Boulvain M, Doh AS, Petignat P. Awareness of HPV and cervical cancer prevention among Cameroonian Health Workers. BMC Women's Health 11(45). Http ://doi.org/10.1186/1472-6874-11-45.
- (28) Diani YT, Panozzo CA, Ramogola-Masire D, Steinhoff AP. A crosssectional study of HPV vaccine acceptability in Gaborone B o t s w a n a . *P l u s ONE*.2011;**6**(10):25481
- (29) Kristina T, Naushin N, Laurie E, Katherine R. Parental knowledge, attitude and behaviours towards Human papilloma virus vaccination for their children: A systemic review from 2001 to 2011.*Obstet Gynaecolint*.2012;**2012**:921236
- (30)Patel H, Pcolkina K, Strazdina K, Viberga I, Sherman SM, Tincello

DG et al. Awareness of HPV infection and altitudes towards HPV vaccination among Latvian adolescents. *Int J Gynecol Obstet* 2017;**137**(2):138-144

- (31) Iwegbe OA, Ugboaja OJ, Monago NE. Prevalence and determinants of unmet need for family planning in Nnewi, South-east Nigeria. *International journal of medicine and medical sciences* 2009;1(8):325-329
- (32)Urassa W, Moshiro C, Chalamalilla F, Mhalu ES. Risky sexual practices among youth attending a sexually transmitted infection clinic in Des es Salaam, Tanzania. *BMC infectious disease*.2008;**8**(1):159
- (33)Lam JU1, Rebolj M, Dugué PA, Bonde J, von Euler-Chelpin M, Lynge E.Condom use in prevention of Human Papillomavirus

infections and cervical neoplasia: systematic review of longitudinal studies. *J Med Screen*. 2014;**21**(1):38-50

- (34)Sylvia BD, Walter AO, Noel TB, Keawango A, Smith JS. HPV vaccine acceptability among Kenyan women. *Vaccine* 2010;**28**(31):4864-4867.
- (35)Paljak M. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges. *Clin Microbiol Infect* 2012;**18**(5):64-69
- (36)Widgren K, Simonsen J, Valentinerbranth P, Molbak K. Uptake of human papilloma virus -vaccination within the free-ofcharge children vaccination program in Denmark. *Vaccine* 2011; **29**:9663-9667.